RxDoctor Payments Data

Magdi Tageldin, MD

Addiction Psychiatry · Spanish Fort, ALNPI 1679661102

Payments from drug & device makers

$4,041in general payments, 2019–2025

Across 225 payments — averaging $17.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$949
  • Alkermes, Inc.$867
  • Johnson & Johnson$402
  • AbbVie$195
  • Sunovion Pharmaceuticals Inc.$170
  • plus $404 from 8 others

What the payments were for

  • Food & beverage$3,78494%
  • Education$2576%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few addiction psychiatry providers in Alabamato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$8,825
Medicare patients
64
Services billed
230

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate348$1,077,198
Abilify MaintenaAripiprazole123$335,795
Invega TrinzaPaliperidone Palmitate34$268,543
AristadaAripiprazole Lauroxil44$142,991
IngrezzaValbenazine Tosylate11$95,450
VraylarCariprazine Hcl42$62,998
RexultiBrexpiprazole36$58,077
CaplytaLumateperone Tosylate23$39,496
LybalviOlanzapine/Samidorphan Malate12$20,892
Oxcarbazepine144$8,681
Aripiprazole248$6,909
Risperidone OdtRisperidone30$6,902
Haloperidol Decanoate118$4,967
Divalproex Sodium199$4,074
Mirtazapine154$4,074

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$402$1,345,741382 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$1,053$393,872159 claims
Alkermes, Inc.Aristada, Lybalvi$867$163,88256 claims
Neurocrine Biosciences, Inc.Ingrezza$32$95,45011 claims
AbbVieVraylar$195$62,99842 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$949$39,49623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few addiction psychiatry providers in Alabamaon file to place this against a meaningful peer group, so we don't.

Other addiction psychiatry in Spanish Fort

Where these figures come from

Is this you, or does something look wrong? →